Minerva Neurosciences (NERV) Payables (2013 - 2026)
Minerva Neurosciences (NERV) posted Payables of $2.1 million for Q1 2026, up 231.12% on a QoQ basis from $639707.0 in Q4 2025, and up 231.0% year-over-year from $639946.0 in Q1 2025.
Minerva Neurosciences (NERV) Payables (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Payables history runs 14 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- Quarterly Payables rose 231.0% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 231.0% YoY) and the FY2025 annual result came in at $639707.0, down 60.21% from the prior year.
- Payables was $2.1 million for Q1 2026 at Minerva Neurosciences, up from $639707.0 in the prior quarter.
- Across five years, Payables topped out at $2.1 million in Q1 2026 and bottomed at $298251.0 in Q2 2023.
- A 5-year average of $1.1 million and a median of $960998.0 in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables sank 80.37% — and 2026, when it soared 231.0%.
- Minerva Neurosciences' Payables stood at $969667.0 in 2022, then surged by 86.18% to $1.8 million in 2023, then decreased by 10.94% to $1.6 million in 2024, then plunged by 60.21% to $639707.0 in 2025, then soared by 231.12% to $2.1 million in 2026.
- Business Quant data shows NERV's Payables at $2.1 million in Q1 2026, $639707.0 in Q4 2025, and $944492.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | 2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.12 Mn |
| Dec 31, 2025 | 639,707.00 |
| Sep 30, 2025 | 944,492.00 |
| Jun 30, 2025 | 896,799.00 |
| Mar 31, 2025 | 639,946.00 |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 553,192.00 |
| Jun 30, 2024 | 828,345.00 |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 1.81 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 298,251.00 |
| Mar 31, 2023 | 960,998.00 |
| Dec 31, 2022 | 969,667.00 |
| Sep 30, 2022 | 532,888.00 |
| Jun 30, 2022 | 1.52 Mn |
| Mar 31, 2022 | 1.59 Mn |
| Dec 31, 2021 | 1.85 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 1.59 Mn |